Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on September 15, 2026, inducement grants (the “Inducement Grants”) were made to James Gute, the recently appointed Chief Commercial Officer of the Company, and two other employees in connection with the commencement of their employment. The Inducement Grant to Mr. Gute consisted of 260,315 restricted stock Units (“RSUs”) representing 260,315 shares of Qua.

Business Wire • Sep 17, 2026

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of the company. In this new role, he will provide medical and clinical leadership across Quanterix, partnering closely with the company's Diagnostics, Scientific, R&D, Regulatory, and Commercial teams, to advance Quanterix's innovative technologies and application.

Business Wire • Sep 14, 2026

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer's Blood Test

Quanterix NASDAQ: QTRX CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma markets.

MarketBeat • Aug 16, 2026

Quanterix Q2 Earnings Call Highlights

Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.

MarketBeat • Aug 10, 2026

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 10, 2026

Quanterix Releases Financial Results for the Second Quarter of 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to im.

Business Wire • Aug 10, 2026

Quanterix Names Jim Gute Chief Commercial Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focu.

Business Wire • Aug 10, 2026

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the C.

Business Wire • Aug 6, 2026

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10, 2026, at 8:30 AM ET, to discuss its second quarter 2026 financial results. Quanterix will issue a press release regarding its second quarter 2026 financial results prior to the conference call on Monday, August 10, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.c.

Business Wire • Aug 4, 2026

Quanterix: Trading Below 1x Sales Despite A Changing Story

Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base for recurring revenue. The Alzheimer's blood test and broader biomarker platform offer significant growth potential, though execution and adoption risks remain.

Seeking Alpha • Jul 20, 2026